Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 2/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509381 | 1.00 | DDAH1 (0.43) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL3043120 | 0.98 | DDAH1 (0.43) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL19019937 | 0.90 | OTC (0.50) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL1951953 | 0.90 | OTC (0.50) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL1953200 | 0.89 | OTC (0.49) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL30409031 | 0.89 | OTC (0.49) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL24788157 | 0.86 | OTC (0.47) | DDAH1OTCNOS3NOS1NOS2 | |
| SCHEMBL2236422 | 0.83 | DDAH1 (0.50) | DDAH1OTCTSHRHPGDCYP1A2 | |
| SCHEMBL2236418 | 0.83 | DDAH1 (0.50) | DDAH1OTCTSHRHPGDCYP1A2 | |
| SCHEMBL24788082 | 0.81 | GLP1R (0.45) | DDAH1OTCNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | DDAH1 3491/4885OTC 4591/4885NOS3 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.